1. Baseline and Time-Averaged Values Predicting Residual Renal Function Decline Rate in Japanese Peritoneal Dialysis Patients
- Author
-
Kazuya Honda, Yuka Kamijo, Keizo Maeda, Kiyotaka Uchiyama, Ryuji Tsujimoto, Akane Yanai, Mai Yanagi, Keisuke Ono, and Yoshitaka Ishibashi
- Subjects
Diminution ,Angiotensin receptor ,medicine.medical_specialty ,Creatinine ,biology ,business.industry ,medicine.medical_treatment ,030232 urology & nephrology ,Urology ,Renal function ,Angiotensin-converting enzyme ,Hematology ,030204 cardiovascular system & hematology ,Peritoneal dialysis ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Mean blood pressure ,Blood pressure ,chemistry ,Nephrology ,biology.protein ,Medicine ,business - Abstract
Residual renal function (RRF) is a strong prognostic factor of morbidity and mortality in patients undergoing peritoneal dialysis (PD). We determined predictors of the RRF rate of decline using both baseline values and time-averaged ones. We retrospectively analyzed 94 patients being treated with PD at the Japanese Red Cross Medical Center. The decline rate of RRF was calculated by a diminution in the weekly renal Kt/V between the first and last follow up divided by follow-up years. The mean follow-up period was 2.28 years, and the mean decline rate of weekly renal Kt/V was 0.25 per year. A multivariate analysis using baseline parameters identified dialysis-to-plasma ratios of creatinine at 4 h (P = 0.02), urinary protein (P = 0.02), and mean blood pressure (MBP) (P < 0.01) as being positively associated with the RRF rate of decline, while the use of angiotensin converting enzyme inhibitor (ACEI)/angiotensin receptor blocker (ARB) had a negative correlation (P = 0.03). When using time-averaged values as independent variables, a lower weekly total renal Kt/V (P < 0.0001), higher urinary protein (P < 0.0001), and higher MBP (P = 0.04) independently predicted a faster RRF rate of decline. We demonstrated that PD patients with a lower MBP and lower urinary protein both at baseline and throughout their PD duration had a slower RRF rate of decline. We recommend strict control of blood pressure and anti-proteinuric therapy for PD patients.
- Published
- 2017
- Full Text
- View/download PDF